MNKD Insider Trading

Insider Ownership Percentage: 3.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $2,696,774.66

MannKind Insider Trading History Chart

This chart shows the insider buying and selling history at MannKind by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M$0$1MTotal Insider BuyingTotal Insider Selling

MannKind Share Price & Price History

Current Price: $5.97
Price Change: Price Decrease of -0.14 (-2.29%)
As of 01/30/2025 05:00 PM ET

This chart shows the closing price history over time for MNKD up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MarAprMayJunJulAugSepOctNovDecJan$6.11Closing price on 01/29/25:

SEC Filings (Institutional Ownership Changes) for MannKind (NASDAQ:MNKD)

49.55% of MannKind stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at MNKD by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$327kbought$1.63MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M$0$20MTotal InflowsTotal Outflows
MannKind logo
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Read More on MannKind

Today's Range

Now: $5.97
Low: $5.91
High: $6.16

50 Day Range

MA: $6.41
Low: $5.93
High: $7.02

52 Week Range

Now: $5.97
Low: $3.17
High: $7.63

Volume

1,693,949 shs

Average Volume

1,941,639 shs

Market Capitalization

$1.65 billion

P/E Ratio

85.29

Dividend Yield

N/A

Beta

1.29

Who are the company insiders with the largest holdings of MannKind?

MannKind's top insider shareholders include:
  1. Michael Castagna (CEO)
  2. Steven B Binder (EVP)
  3. Steven B Binder (Director)
  4. Stuart A Tross (Insider)
  5. David Thomson (EVP)
  6. Steven B Binder (CFO)
Learn More about top insider investors at MannKind.

Who are the major institutional investors of MannKind?

MannKind's top institutional shareholders include:
  1. TSP Capital Management Group LLC — 0.91%
  2. 180 Wealth Advisors LLC — 0.76%
  3. Hennion & Walsh Asset Management Inc. — 0.09%
  4. Calamos Advisors LLC — 0.07%
  5. China Universal Asset Management Co. Ltd. — 0.02%
  6. New Wave Wealth Advisors LLC — 0.02%
Learn More about top institutional investors of MannKind stock.

Which institutional investors are selling MannKind stock?

During the last quarter, MNKD stock was sold by these institutional investors:
  1. Calamos Advisors LLC
  2. International Assets Investment Management LLC
  3. SG Americas Securities LLC
  4. Wealth Enhancement Advisory Services LLC
  5. Hennion & Walsh Asset Management Inc.
Within the last year, company insiders that have sold MannKind company stock include:
  1. Michael Castagna (CEO)
  2. Steven B Binder (EVP)
  3. Steven B Binder (Director)
  4. Stuart A Tross (Insider)
  5. David Thomson (EVP)
Learn More investors selling MannKind stock.

Which institutional investors are buying MannKind stock?

During the previous quarter, MNKD stock was bought by institutional investors including:
  1. New Wave Wealth Advisors LLC
  2. 180 Wealth Advisors LLC
  3. TSP Capital Management Group LLC
  4. China Universal Asset Management Co. Ltd.